In Their Own Words: Wall Street's View of Health Care Reform
This article was originally published in RPM Report
As health reform enters a critical phase in Washington, the investment community is paying more attention than ever to the debate in Congress.
You may also be interested in...
There are multiple political strategies playing out in Washington on health care reform that will directly impact the biopharma industry. In the end biopharma will trade margins for volume. The RPM Report makes predictions on what will make it into the final health reform bill.
The withdrawal of Tom Daschle from consideration as HHS Secretary means there won't be a single focus for health care policy during the upcoming health care reform debate. Can two powerful Democratic legislators and the Obama budget team fill the void?
As the presidential race heats up, health care executives say they have many reasons to be excited–and nervous. Boston Consulting Group reviews an industry-wide survey on the implications of the candidates’ health care proposals for the pharma and device industries.